Physician profile
Karma S Carty
NPI 1700495306
$1,568.03
in general payments reported to CMS, 2019-2025
18 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.01 · 2022: $48.49 · 2023: $291 · 2024: $705 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $453.61 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.32 | 2023-2025 | Jardiance |
| Dexcom, INC. | $185.14 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $125.78 | 2024-2025 | Freestyle Libre 3, Triclip |
| Medtronic, INC. | $124.99 | 2025 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $110.79 | 2024-2025 | |
| Novo Nordisk INC | $75.61 | 2022-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $56.88 | 2024-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $38.76 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $33.86 | 2024 | Arcalyst |
| Pfizer INC. | $30.48 | 2024 | |
| Boston Scientific Corporation | $24.11 | 2025 | Watchman Access System |
| Lexicon Pharmaceuticals, INC. | $21.29 | 2024 | |
| Ascensia Diabetes Care US INC. | $18.14 | 2023 | |
| Insulet Corporation | $17.01 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.71 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.31 | 2025 | Camzyos |
| Esperion Therapeutics, INC. | $16.24 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karma Carty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.